PDF(Pubmed)
Abstract：
Glucagon-like peptide 1 (GLP-1) agonists are commonly used in the management of type 2 diabetes due to their glucose-lowering effects and potential cardiovascular benefits. While generally well-tolerated, here we report a unique case associated with GLP-1 therapy. A 57-year-old male with a history of type 2 diabetes developed mild abdominal pain with no nausea or vomiting approximately four months after increasing the dose of GLP-1 therapy. Imaging studies revealed mesenteric vein thrombosis and an enlarged pancreatic head. Endoscopic ultrasound with biopsies was completed, which confirmed acute pancreatitis. The patient was promptly treated with a heparin drip and supportive care. The GLP-1 agonist was discontinued. This case highlights a rare but critical adverse event associated with GLP-1 receptor agonists as well as the importance of considering unusual complications in patients initiating such therapy. Further research is warranted to elucidate the underlying mechanisms and risk factors for these adverse events.
摘要：
胰高血糖素样肽1（GLP-1）激动剂由于其降糖作用和潜在的心血管益处而通常用于2型糖尿病的治疗。虽然一般耐受性良好，在此,我们报道了一个与GLP-1治疗相关的独特病例.一名57岁有2型糖尿病病史的男性在增加GLP-1治疗剂量后约四个月出现轻度腹痛，无恶心或呕吐。影像学检查显示肠系膜静脉血栓形成和胰头增大。完成了内窥镜超声活检，证实了急性胰腺炎。患者立即接受肝素滴注和支持治疗。停用GLP-1激动剂。该病例强调了与GLP-1受体激动剂相关的罕见但严重的不良事件，以及考虑开始此类治疗的患者中异常并发症的重要性。需要进一步的研究来阐明这些不良事件的潜在机制和风险因素。
